FindTrial
Sign In

A Randomised, Double-Blind, Parallel-Group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum

A Randomised, Double-Blind, Parallel-Group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220354
Enrollment
Unknown
Registered
2007-03-01
Start date
2007-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Interventions

investigational material(s) Generic name etc : ZD6474 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Sponsors

AstraZeneca
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both Criteria Inclusion Criteria: - Provision of written informed consent. - Life expectancy of 12 weeks or longer. Exclusion Criteria: - Pregnancy, breast feeding or female patients wishing to become pregnant. - Treatment with a non-approved or investigational drug within 30 days before enrolment

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy Primary Outcomes: To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively Secondary Outcomes: To assess the tolerability, safety, disease control rate, duration of response, time to progression, changes in quality of life and tumour-related and overall symptom improvements, and to characterise the PK and PK-PD relationship—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026